Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

被引：25
|
作者：
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
机构：
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页码：S1314 / S1315
页数：2
相关论文
共 50 条
  • [21] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (vol 16, pg 522, 2015)
    Eggermont, A. M. M.
    Chiarion-Sileni, V
    Grob, J-J
    LANCET ONCOLOGY, 2015, 16 (06): : E262 - E262
  • [22] Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safely results from the EORTC 18071 phase III trial
    Eggerrnont, Alexander M.
    Chiarion-Sileni, Vanna
    Grob, Jean Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo Antonio
    Richards, Jon M.
    Lobbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Konto, Cyril
    Gurunath, Ravichandra Karra
    de Pril, Veerle
    Suciu, Stefan
    Testorl, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (vol 16, pg 522, 2015)
    Eggermont, A. M. M.
    Chiarion-Sileni, V
    Grob, J-J
    LANCET ONCOLOGY, 2016, 17 (06): : E223 - E223
  • [24] Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
    Kennedy, Oliver J.
    Kicinski, Michal
    Valpione, Sara
    Gandini, Sara
    Suciu, Stefan
    Blank, Christian U.
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna M.
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Robert, Caroline
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Mandala, Mario
    EUROPEAN JOURNAL OF CANCER, 2022, 165 : 97 - 112
  • [25] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
    Eggermont, Alexander M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew Mark
    Meshcheryakov, Andrey
    Khattak, Muhammad
    Carlino, Matteo S.
    Sandhu, Shahneen Kaur
    Puig, Susana
    Ascierto, Paolo Antonio
    Christopher, Alexander
    Van Akkooi, Jonathan
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
    Luke, Jason J.
    Ascierto, Paolo A.
    Khattak, Muhammad A.
    de la Cruz-Merino, Luis
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1619 - 1624
  • [27] Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
    Coens, Corneel
    Suciu, Stefan
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo A.
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Bottomley, Andrew
    Kotapati, Srividya
    de Pril, Veerle
    Testori, Alessandro
    Eggermont, Alexander M. M.
    LANCET ONCOLOGY, 2017, 18 (03): : 393 - 403
  • [28] Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
    Eggermont, Alexander M. M.
    Chiarion-Sileni, Vanna
    Grob, Jean Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo Antonio
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Hosein, Fareeda
    de Pril, Veerle
    Kicinski, Michal
    Suciu, Stefan
    Testori, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
    Eggermont, A. M. M.
    Chiarion-Sileni, V.
    Grob, J-J.
    Dummer, R.
    Wolchok, J. D.
    Schmidt, H.
    Hamid, O.
    Robert, C.
    Ascierto, P. A.
    Richards, J. M.
    Lebbe, C.
    Ferraresi, V.
    Smylie, M.
    Weber, J. S.
    Taitt, C.
    de Pril, V.
    de Schaetzen, G.
    Suciu, S.
    Testori, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Phase III KEYNOTE-716 Study of Pembrolizumab (KEYTRUDA®) as adjuvant Therapy for Patients with resected Stage IIB or IIC Melanoma: significant Improvement in distant metastasis-free Survival versus Placebo
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
12345